Importantly, a previous study indicated that targeting FPR1 by ICT12035, a selective small molecule antagonist, can provide a new avenue for the therapy of cancers (31). Therefore, further investigation of FPR1 antagonists can provide opportunities for more efficient treatment of cancers, including bladder cancer. The gene discussed is FPR1; the disease is urinary bladder carcinoma.